Frank Leonard has served as Executive Vice President and President, Novocure Oncology, since January 2024. He is responsible for Novocure’s global commercial business operations.

Mr. Leonard most recently served as President, CNS Cancers U.S., overseeing U.S. business operations for our glioblastoma (GBM) indications.

Mr. Leonard previously served as Chief Development Officer from Sept. 2020 to Sept. 2022. In this role, he was responsible for engineering, product development, business development and the overall strategic and operational leadership of Novocure’s innovation platforms.

Mr. Leonard joined Novocure in 2010 to help prepare the company for the commercial launch of Optune^®, now called Optune Gio^®. In prior roles, Mr. Leonard established Novocure’s health policy and business development groups, and additionally led various finance functions.

Mr. Leonard has served as a director of the Medical Device Manufacturers Association (MDMA) since 2023. Prior to joining Novocure, he was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.